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Abstract15
We formulate, parameterise and analyse a mathematical model of the meval-
onate pathway, a key pathway in the synthesis of cholesterol. Of high clini-
cal importance, the pathway incorporates rate limiting enzymatic reactions
with multiple negative feedbacks. In this work we investigate the pathway
dynamics and demonstrate that rate limiting steps and negative feedbacks
within it act in concert to tightly regulate intracellular cholesterol levels.
Formulated using the theory of nonlinear ordinary dierential equations and
parameterised in the context of a hepatocyte, the governing equations are
analysed numerically and analytically. Sensitivity and mathematical analysis
demonstrate the importance of the two rate limiting enzymes 3-hydroxy-3-
methylglutaryl-CoA reductase and squalene synthase in controlling the con-
centration of substrates within the pathway as well as that of cholesterol.
The role of individual feedbacks, both global (between that of cholesterol
and sterol regulatory element-binding protein 2; SREBP-2) and local in-
ternal (between substrates in the pathway) are investigated. We nd that
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whilst the cholesterol SREBP-2 feedback regulates the overall system dy-
namics, local feedbacks activate within the pathway to tightly regulate the
overall cellular cholesterol concentration. The network stability is analysed
by constructing a reduced model of the fall pathway and is shown to exhibit
one real, stable steady-state. We close by addressing the biological question
as to how farnesyl-PP levels are aected by CYP51 inhibition, and demon-
strate that the regulatory mechanisms within the network work in unison to
ensure they remain bounded.
Keywords: nonlinear ordinary dierential equation, feedback, HMGCR,16
squalene synthase17
1. Introduction18
The mevalonate pathway is an important metabolic pathway present in all eu-19
karyotes, fungi and some bacteria [6, 13]. It is responsible for many processes20
within the cell including biosynthesis of cholesterol, cell wall maintenance,21
hormone production, protein lipidation and anchoring and is part of steroid22
biosynthesis.23
The body produces around 80% of cholesterol it needs [40]. A large percent-24
age of this is synthesised by the liver via a series of reactions. In mammalian25
cells cholesterol is a substrate for a number of other reactions [6]. Over ac-26
cumulation of cholesterol can lead to cellular toxicity [18], whilst insucient27
cholesterol levels result in compromised cell structure and function. Thus28
it is important that cholesterol levels are tightly regulated within the cell.29
This is known as cellular cholesterol homeostasis and it works by balanc-30
ing the inux, utilisation and eux of cholesterol to maintain intracellular31
concentrations within a narrow range of concentration.32
The mevalonate pathway is comprised of two genetic synthesis cascades which33
react with intermediate substrates to form cholesterol and has been com-34
prehensively detailed by [22]. Sterol regulatory element-binding protein 235
(SREBP-2) co-regulates the gene transcription of 3-hydroxy-3-methylglutary36
coenzyme A reductase (HMGCR) and squalene synthase. This regulation is37
cholesterol dependent [13]. When cholesterol levels are high, SREBP-2 is38
bound in a complex with cholesterol anchoring it to the cell membrane ren-39
dering SREBP-2 inactive. In low cholesterol concentrations the complex40
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unbinds and through a complex series of translocation and proteolytic pro-41
cessing steps SREBP-2 is released, relocates to the nucleus and binds to tar-42
get DNA stimulating increased transcription leading to increased production43
of the enzymes such as HMGCR and squalene synthase [6].44
The central anabolic cascade of the pathway is initiated by the binding of45
HMGCoA to the active site of HMGCR, which then catalyses its conversion46
into mevalonate. Mevalonate is then converted to geranyl pyrophosphate47
(geranyl-PP), farnesyl pyrophosphate (farnesyl-PP), squalene (via the inter-48
action between farnesyl-PP and squalene synthase), lanosterol and nally49
after some 19 further steps [11], cholesterol. A rate limiting step in this50
chain of biosynthesis is the reduction of HMGCoA catalysed by HMGCR51
[13].52
The tight control of cholesterol concentration is thought possible by a number53
of negative feedback loops that regulate HMGCR and receptors dependent54
on intracellular cholesterol concentrations [14, 35]. Feedbacks from farnesyl-55
PP [10] and lanosterol accelerate HMGCR degradation [4], and it has been56
suggested that geranyl-PP plays a similar role. Cholesterol has been shown57
to accelerate squalene synthase degradation [10] and oxygenated derivatives58
of cholesterol have been identied in HMGCR degradation [9].59
Many of the products formed from the mevalonate pathway are involved in60
other cell signalling cascades. Farnesyl-PP is a major branch point in the61
pathway which is responsible for producing six other substrates used in vital62
cellular functions. Excessive amounts of farnesyl-PP have been suggestively63
linked to tumours and Alzheimers disease [7, 32]. Inhibitors of the mevalonate64
pathway are used in cardiovascular therapy (statins) and as anti-fungal agents65
(CYP51 inhibitors) in crop protection. The extent to which altering this66
pathway is associated with the carcinogenic and developmental eects of67
CYP51 inhibitors has been debated [23, 26].68
Mathematical modelling of cholesterol biosynthesis pathways has to date fo-69
cused on specic aspects of the pathway. Kervizic and Corcos [19] developed70
a boolean model of the pathway which focused on demonstrating the role of71
SREBP-2 in synthesising cholesterol and the eect of statins on the process.72
Their model showed good agreement with experimental known functioning of73
the pathway in respect of statin applications. Watterson and colleagues [45]74
formulated an ordinary dierential equation (ODE) model of the pathway75
to understand the eect of the immune response and statins on the overall76
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pathway. Using experimental data from macrophages, their work shows the77
gradual reduction in pathway activity as a result of the innate immune re-78
sponse, versus the more step like change imparted by statins. A recent paper79
by Bhattacharya et al. [2] formulated and analysed a three variable nonlin-80
ear ODE simplied model of the pathway that incorporates a description of81
HMGCR mRNA, HMGCR protein and cholesterol biosynthesis. The syn-82
thesis of HMGCR mRNA is controlled by a negative feedback loop, whereby83
cholesterol is able to bind to free SREBP-2. Model results and analysis84
demonstrate the system exhibits one real stable steady-state which is mono-85
tonic, periodic or damped periodic under certain model parameterisations as86
a result of cholesterol's negative regulation of SREBP-2.87
In this paper we seek here to expand our knowledge of cholesterol biosynthesis88
by deriving and solving a nonlinear ODE model of the mevalonate choles-89
terol biosynthesis pathway. Our aim is to better understand the role of the90
overall network structure in dynamically regulating cholesterol biosynthesis,91
in particular that of multiple synthesis pathways and feedbacks. We begin in92
Section 2 by presenting our main model of the pathway which incorporates93
the core regulation mechanisms and feedbacks within the signalling cascade.94
An ODE model of the pathway is derived from rst principles in Section 3,95
which is subsequently parameterised and solved numerically in Section 4.96
The results of a local sensitivity analysis are presented in Section 5 and the97
role of the second rate limiting step in the pathway between farnesyl-PP98
and squalene synthase is analysed in detail in Section 6. The eect of the99
numerous feedbacks within the pathway are analysed in Section 9 before a100
steady-state stability analysis of a model reduction of the full network model101
is presented in Section 7. Negative feedbacks may lead to a network ex-102
hibiting oscillatory type behaviour and as such we examine whether such103
solutions may be observed for certain parameterisations of the full model in104
Section 8. We test the hypothesis that the application of CYP51 inhibitors105
leads to increased levels of farnesyl-PP, via inhibition of cholesterol produc-106
tion following that of lanosterol, in Section 10. Our results and conclusions107
are discussed in Section 11.108
2. The Mevalonate Pathway109
Given the complexity of the full pathway we consider here a reduction, in-110
corporating the details outlined in the Introduction, which captures the core111
4
synthesis processes, feedbacks and branch points associated with cholesterol112
regulation as shown in Figure 1. Essentially, substrates and enzymes that113
form sequential linear steps in the pathway and which are not involved in114
feedbacks or branch points, have been omitted. This leaves three core as-115
pects:116
1. the two genetic transcriptional control pathways of HMGCR and squa-117
lene synthase by SREBP-2;118
2. the central metabolic cascade which synthesises intermediary meval-119
onate products and sterols with controlling steps using the enzymes120
HMGCR and squalene synthase; and121
3. negative feedback controls, including negative regulation of SREBP-2122
by cholesterol and the concentration dependent feedbacks from sterol123
and non-sterol products aecting the HMGCR and squalene synthase124
degradation rates.125
In high cholesterol concentrations SREBP-2 is bound to a cholesterol molecule126
anchoring it to the intracellular membrane, represented in Figure 1 by the127
3/ 3 negative feedback. Here 3 represents the association reaction, whilst128
 3 the disassociation reaction. In low cholesterol concentrations, SREBP-2129
disassociates from the cholesterol molecule allowing it, via a series of inter-130
mediate steps, to produce an active transcription factor that relocates to the131
nucleus to act upon the DNA stimulating endogenous production of HMGCR132
and squalene synthase. This is represented in Figure 1, by the two reactions133
1/ 1, through 1 to 3 and 2/ 2, through 2 to 4. In the centre of the134
pathway HMGCR binds with HMGCoA to form an intermediary complex135
which leads to mevalonate production. This is subsequently phosphorylated136
twice then converted to isopentenyl-PP and geranyl-PP. In Figure 1 these137
ve steps are represented as 5. From geranyl-PP, farnesyl-PP is produced.138
It is at this point that squalene synthase reacts with farnesyl-PP and this139
complex produces squalene. Squalene produces squalene-2,3-epoxide after140
which lanosterol is formed. We represent these two steps by 8. There are a141
further 19 reactions from lanosterol until cholesterol [11] which we approxi-142
mate by the parameter 9. This approximation allows for the simplication143
of an otherwise already under parameterised system.144
There are a number of feedbacks within the pathway shown in Figure 1.145
Goldstein and Brown [4] found that sterols caused a negative feedback on146
HMGCR production but hypothesised sterols were not the only inhibitors.147
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Figure 1: A simplied model of the mevalonate pathway. Arrows show forward reac-
tions, circles show stimulative reactions and horizontal bars indicate inhibition. Here
 indicates the removal of a product from the pathway, either by degradation or use
in another process. There are three main focal points to the pathway; the two genetic
pathways of HMGCR and squalene synthase, the central metabolic cascade and the
regulatory feedbacks (dashed lines).
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Hence we have concentration dependent feedbacks from lanosterol ( K7) and148
cholesterol ( K8) that up-regulate the degradation of HMGCR. It has been149
suggested that geranyl-PP also up-regulates HMGCR degradation [14] ( K6)150
and recent ndings by Foresti et al. [10] have shown farnesyl-PP is linked to151
HMGCR degradation ( K9). Foresti et al. also show a similar concentration152
dependent reaction between cholesterol and the rate of squalene synthase153
degradation ( K10).154
3. Mathematical model155
In this section we derive a system of non-linear ODEs to describe the reaction156
network detailed in Section 2 using the law of mass action. Details on the157
biochemistry underlying each step within the pathway are given in Appendix158
A. Applying the law of mass action to equations (A.1) - (A.6) gives159
dgh
dt
=  1sbh   1sxhgh; (1)
dgss
dt
=  2sbss   2sxsgss; (2)
ds
dt
= xh 1sbh   xh1sxhgh + xs 2sbss   xs2sxsgss   3cxcs+  3cb; (3)
dsbh
dt
=   1sbh + 1sxhgh; (4)
dsbss
dt
=   2sbss + 2sxsgss; (5)
d mh
dt
= 1sbh   1 mh; (6)
d mss
dt
= 2sbss   2 mss; (7)
dhr
dt
= 3 mh +  4hb   4hrhc + 5hb
 3hr

1 + hg
gpp
gpp + K6
+ hf
fpp
fpp + K9
+ hl
l
l + K7
+ hc
c
c+ K8

;(8)
dss
dt
= 4 mss +  5 fbpp   5ss f 2pp + 7 fbpp   4ss

1 + sc
c
c+ K10

; (9)
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dhc
dt
=  4hb   4hrhc + !; (10)
dhb
dt
=   4hb + 4hrhc   5hb   3hb; (11)
dgpp
dt
= 5hb   5gpp   6gpp; (12)
d fpp
dt
= 6gpp   6 fpp   25ss f 2pp + 2 5 fbpp; (13)
d fbpp
dt
= 5ss f
2
pp    5 fbpp   7 fbpp   4 fbpp; (14)
dsq
dt
= 7 fbpp   8sq; (15)
dl
dt
= 8sq   7l   9l; (16)
dc
dt
= 9l   8c+ xc 3cb   xc3cxcs; (17)
dcb
dt
= 3c
xcs   3cb; (18)
where, with square brackets denoting concentration,161
gh = [Gh]; gss = [Gss]; s = [S]; sbh = [Sbh]; sbss = [Sbss];
mh = [Mh]; mss = [Mss]; hr = [Hr]; ss = [Ss]; hc = [Hc];
hb = [Hb]; gpp = [Gpp]; fpp = [Fpp]; fbpp = [Fbpp]; sq = [Sq];
l = [L]; c = [C]; and cb = [Cb];
and the system is closed with the initial conditions162
gh(0) = gh0; gs(0) = gs0; s(0) = s0; sbh(0) = 0; sbss(0) = 0;
mh(0) = mh0; mss(0) = mss0; hr(0) = hr0; ss(0) = ss0;
hc(0) = hc0; hb(0) = 0; gpp(0) = 0; fpp(0) = 0; fbpp(0) = 0;
sq(0) = 0; l(0) = 0; c(0) = 0 and cb(0) = 0; (19)
at t = 0163
Many of the initial conditions are assumed equal to zero in order to under-164
stand the overall dynamical response of the system. The feedbacks acting165
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on HMGCR and squalene synthase degradation, equations (22) and (23) re-166
spectively, are dependent on geranyl-PP, farnesyl-PP, lanosterol and choles-167
terol concentrations. We thus assume these follow sigmoidal shape kinet-168
ics [24], where K6;7;8;9;10 are the respective Michaelis-Menten constants and169
hg; hf ; hl and hc, are dimensionless weighting constants representing the170
additional eect of geranyl-PP, farnesyl-PP, lanosterol and cholesterol to that171
of the natural rate of HMGCR degradation, respectively, and sc is that of a172
similar eect of cholesterol on the natural decay rate of squalene synthase.173
By invoking conservation of certain entities within the pathway and employ-174
ing quasi-equilibrium approximations (see Appendix B) equations (1) to (17)175
are reduced to176
d mh
dt
=
1
1 +

K1(1+(
c
K3
)xc )
s0
xh   1 mh; (20)
d mss
dt
=
2
1 +

K2(1+(
c
K3
)xc )
s0
xs   2 mss; (21)
dhr
dt
= 3 mh +  4hb   4hrhc + 5hb
 3hr

1 + hg
gpp
gpp + K6
+ hf
fpp
fpp + K9
+ hl
l
l + K7
+ hc
c
c+ K8

;
(22)
dss
dt
= 4 mss +  5 fbpp   5ss f 2pp + 7 fbpp   4ss

1 + sc
c
c+ K10

; (23)
dhc
dt
=  4hb   4hrhc + !; (24)
dhb
dt
=   4hb + 4hrhc   5hb   3hb; (25)
dgpp
dt
= 5hb   5gpp   6gpp; (26)
d fpp
dt
= 6gpp   6 fpp   25ss f 2pp + 2 5 fbpp; (27)
d fbpp
dt
= 5ss f
2
pp    5 fbpp   7 fbpp   4 fbpp; (28)
9
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dsq
dt
= 7 fbpp   8sq; (29)
dl
dt
= 8sq   7l   9l; (30)
dc
dt
=
9l   8c
1  xc(s0 + xhs0bh + xss0bss)
; (31)
where s0bss, s0bh and s0 are given by equations (B.9), (B.10) and (B.8) respec-178
tively, and 0 indicates dierentiation with respect to c. The initial conditions179
are given by180
mh(0) = mh0; mss(0) = mss0; hr(0) = hr0; ss(0) = ss0;
hc(0) = hc0; hb(0) = 0; gpp(0) = 0; fpp(0) = 0; fbpp(0) = 0;
sq(0) = 0; l(0) = 0 and c(0) = 0: (32)
3.1. Non-dimensionalisation181
Equations (20) to (32) are non-dimensionalised according to the following182
rescalings183
t = t7 ; mh = mh0mh; mss = mh0mss;
hr = ssThr;
Ss = ssT ss; hc = hcThc; hb = hcThb; gpp = hcT gpp;
fpp = hcTfpp; fbpp = hcTfbpp; sq = hcT sq; l = hcT l; c = hcT c; (33)
where ssT and hcT are the experimentally determined total concentrations of184
squalene synthase and HMG-CoA in a resting hepatocyte cell [5]. Substitut-185
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ing these rescalings into equations (20) through (32), we obtain186
dmh
dt
=
1
1 +

1(1 + (
c
3
)xc)
xh   1mh; (34)
dmss
dt
=
2
1 +

2(1 + (
c
3
)xc)
xs   2mss; (35)
dhr
dt
= 3mh +  4hb   4hrhc + 5hb
 3hr

1 + hg
gpp
gpp +K6
+ hf
fpp
fpp +K9
+ hl
l
l +K7
+
hc
c
c+K8

; (36)
187
dss
dt
= 4mss +  5fbpp   5ssf 2pp + 7fbpp  
4ss

1 + sc
c
c+K10

; (37)
dhc
dt
=  4hb   4hrhc + !; (38)
dhb
dt
=   4hb + 4hrhc   5hb   3hb; (39)
dgpp
dt
= 5hb   5gpp   6gpp; (40)
dfpp
dt
= 6gpp   6fpp   25ssf 2pp + 2 5fbpp; (41)
dfbpp
dt
= 5ssf
2
bpp    5fbpp   7fbpp   4fbpp; (42)
dsq
dt
= 7fbpp   8sq; (43)
dl
dt
= 8sq   7l   9l; (44)
dc
dt
=
9l   8c
1  xc(s0s0 + xhgh0s0bh + xsgss0s0bss)
; (45)
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with the non-dimensional initial conditions, at t = 0, given by188
mh(0) = 1; mss(0) = 1; hr(0) = 0; ss(0) = 0; hc(0) = 0;
hb(0) = 0; gpp(0) = 0; fpp(0) = 0; fbpp(0) = 0; sq(0) = 0;
l(0) = 0 and c(0) = 0; (46)
and the non-dimensional parameters summarised in Table 2.189
3.2. Model parameterisation190
Wherever possible data from human liver (hepatocyte G2; HepG2) cells191
was used to inform our parameter values. Where values have been unavail-192
able from HepG2 cells, other sources have included human liver microsomes193
(pieces of the endoplasmic reticulum used in some experimental work) or Chi-194
nese hamster ovary cells. Details regarding the estimation of all parameter195
values is provided in Appendix C, whilst Table 1 summarises each dimen-196
sional parameter, their value and source. Non-dimensional parameters are197
stated in Table 2.198
In cases where no information was available, approximations were rst made199
based on similar occuring reactions and processes, e.g. rates of mRNA200
degradation, as detailed in Appendix C. For instance, rates calculated from201
Bhattacharya et al. [2] regarding HMGCR and cholesterol synthesis, specif-202
ically binding anities and degradation rates relating to HMGCR mRNA,203
HMGCR and cholesterol, were used to initially inform rates corresponding204
to squalene synthase synthesis and degradation as well as (non)sterol pro-205
duction rates. Using Matlab [21] the model was then simulated numerically206
(using the ode15s solver) and analysed via a local sensitivity analysis (coded207
directly into Matlab). The sensitivity analysis was used to ascertain the208
importance of the unknown assumed parameter values in aecting the to-209
tal cholesterol concentration in an heptaocyte. Based on the ndings of this210
analysis, parameter values were then adjusted accordingly (as detailed in Ap-211
pendix C) to ensure the model reproduced previously determined cholesterol212
concentrations [2].213
In the absence of any available data in other cell systems with which to214
compare any determined values, the additional eects of farnesyl-PP, geranyl-215
PP, lanosterol and cholesterol on HMGCR degradation and cholesterol on216
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that of squalene synthase degradation (hg, hf , hl, hc, sc) were set equal217
to unity.218
It is important to note that the utilisation of cholesterol and farnesyl-PP can219
vary depending on other intracellular processes. To simplify our model, we220
have assumed a constant value of cholesterol and farnesyl-PP degradation to221
include cellular utilisation, based on the work by Bhattacharya et al. [2].222
Table 1: Dimensional parameters. Here \Param." denotes parameter, \molec"
molecules, \SqS" squalene synthase.
Param. Description Value Units Reference
mh0 Initial HMGCR mRNA 3:0 109 molec./ml [30]
concentration.
mss0 Initial SqS mRNA 3:0 109 molec./ml [30]
concentration.
ssT Total SqS synthase 7:59 1014 molec./ml [5]
concentration.
hcT Total HMGCoA 1:98 1015 molec./ml [33, 38]
concentration.
s0 Total SREBP-2 8:21 1016 molec./ml [31, 2]
concentration.
gh0 HMGCR gene 2:11 109 molec./ml [41]/This study.
concentration.
gss0 SqS gene 2:11 109 molec./ml This study.
concentration.
1 HMGCR transcription. 5:17 105 molec.ml.s [8, 12]
2 SqS transcription. 4:65 105 molec.ml.s [8, 37]
3 HMGCR translation 3:32 10 2 1/s [39, 17]
4 SqS translation. 1:91 10 2 1/s [39, 36]
5 Geranyl-PP formation. 4:33 10 2 1/s [15, 33, 43]
6 Farnesyl-PP formation. 4:33 10 2 1/s [15, 33, 47]
7 SqS formation. 2:17 10 1 1/s This study.
8 Lanosterol formation. 4:33 10 2 1/s [15, 33, 47]
9 Cholesterol formation. 4:33 10 2 1/s [15, 33, 47]
K1 SREBP-2-HMGCR gene 8:21 1012 molec./ml [29]/This study.
binding anity.
K2 SREBP-2-SqS gene 8:21 1012 molec./ml [29]/This study.
binding anity.
K3 Cholesterol-SREBP-2 1:49 1016 molec./ml [46]/This study.
disassociation constant.
4 HMGCR-HMGCoA 1:39 10 16 mlmolec.s This study.
association.
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 4 HMGCR-HMGCoA 1:75 10 7 1/s This study
disassociation.
5 SqS - Farnesyl-PP 1:76 10 30 ml
2
molec2:s
This study
association.
 5 SqS - Farnesyl-PP 1:75 10 5 1/s This study.
disassociation.
K6 Michaelis-Menten constant 5:00 109 molec./ml This study.
for geranyl-PP/HMGCR
degradation.
K7 Michaelis-Menten constant 5:00 1012 molec./ml This study.
for lanosterol/HMGCR
degradation.
K8 Michaelis-Menten constant 5:00 1017 molec./ml This study.
for cholesterol/HMGCR
degradation.
K9 Michaelis-Menten constant 5:00 1011 molec./ml This study.
for farnesyl-PP/HMGCR
degradation.
K10 Michaelis-Menten constant 5:00 1017 molec./ml This study.
for cholesterol/SqS
degradation.
1 HMGCR mRNA 4:48 10 5 1/s [3]
degradation.
2 SqS mRNA 4:48 10 5 1/s This study.
degradation.
3 HMGCR degradation. 6:42 10 5 1/s [44]
4 SqS degradation. 6:42 10 5 1/s This study.
5 Geranyl-PP degradation. 1:20 10 4 1/s This study.
6 Farnesyl-PP degradation. 1:20 10 4 1/s This study.
7 Lanosterol degradation. 1:20 10 4 1/s This study.
8 Cholesterol degradation. 1:20 10 4 1/s [2]
hg Additional eect of geranyl-PP 1 - This study
on HMGCR degradation. . .
hf Additional eect of farnesyl-PP 1 - This study
on HMGCR degradation. . .
hl Additional eect of lanosterol 1 - This study
on HMGCR degradation. . .
hc Additional eect of cholesterol 1 - This study
on HMGCR degradation. . .
sc Additional eect of cholesterol 1 - This study
on SqS degradation. . .
! HMGCoA production. 3:90 1011 molec./ml This study.
xh Binding sites on HMGCR 3 - [28]
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gene for SREBP-2.
xs Binding sites on SqS 1 - This study.
gene for SREBP-2.
xc Molecules of cholesterol 4 - [46, 16]
to inactivate SREBP-2.
Table 2: Table of non-dimensional parameters, their relation to dimensional ones and
value.
Parameter Description Denition Value
s0 Ratio of SREBP-2 to HMGCoA s0/hcT 41.46
gh0 Ratio of HMGCR gene to SREBP-2 gh0/s0 2:57 10 8
gss0 Ratio of SqS gene to SREBP-2 gss0/s0 2:57 10 8
1 HMGCR mRNA transcription.
1
7 mh0
1:44
2 SqS mRNA transcription.
2
7 mh0
1:29
3 HMGCR translation.
3 mh0
7ssT
1:10 10 3
4 SqS translation.
4 mh0
7ssT
6:29 10 4
5 Geranyl-PP production.
5
7
3:61 102
6 Farnesyl-PP production.
6
7
3:61 102
7 SqS production.
7
7
1:80 103
8 Lanosterol production.
8
7
3:61 102
9 Cholesterol production.
9
7
3:61 102
1 SREBP-2-HMGCR gene binding anity.
K1
s0
1 10 4
2 SREBP-2-SqS gene
K2
s0
1 10 4
binding anity.
3 Cholesterol-SREBP-2 dissociation
K3
hcT
7.5
constant.
4 HMGCR-HMGCoA association.
4ssT
7
8:83 102
 4 HMGCR-HMGCoA disassociation.
 4
7
1:46 10 3
5 SqS-farnesyl-PP
5hcT ssT
7
2:20 104
association.
 5 SqS-farnesyl-PP
 5
7
1:46 10 1
disassociation.
K6 Michaelis-Menten constant
K6
hcT
2:53 10 6
for geranyl-PP/HMGCR degradation.
K7 Michaelis-Menten constant
K7
hcT
2:53 10 3
for lanosterol/HMGCR degradation.
K8 Michaelis-Menten constant
K8
hcT
2:53 102
for cholesterol/HMGCR degradation.
K9 Michaelis-Menten constant
K9
hcT
2:53 10 4
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for farnesyl-PP/HMGCR degradation.
K10 Michaelis-Menten constant
K10
hcT
2:53 102
for cholesterol/SqS degradation.
1 HMGCR mRNA degradation.
1
7
3:73 10 1
2 SqS mRNA degradation.
2
7
3:73 10 1
3 HMGCR degradation.
3
7
5:35 10 1
4 SqS degradation.
4
7
5:35 10 1
5 Geranyl-PP degradation.
5
7
1
6 Farnesyl-PP degradation.
6
7
1
7 Lanosterol degradation.
7
7
1
8 Cholesterol degradation.
8
7
1
! HMGCoA production. !7hc0 0.82
 Ratio of total HMGCoA to SqS.
hcT
ssT
2:61
4. Analysis of numerical results223
In this section we present numerical solutions to equations (34) to (46), pa-224
rameterised by Table 2, obtained using the MATLAB sti dierential equa-225
tion solver ode15s [21]. Results are shown in Figure 2. Time has been re-226
dimensionalised on the x-axis and simulations run until the system reaches227
steady-state.228
Figure 2 shows the initial increase of HMGCR and squalene synthase mRNA;229
a result of no cholesterol being initially present in the system. HMGCR and230
squalene synthase mRNA transcription subsequently leads to their transla-231
tion into their respective proteins. As HMGCR increases it binds to HMG-232
CoA leading to a subsequent decrease in its levels. This substrate-enzyme233
reaction leads to increases in geranyl-PP, farnesyl-PP, bound farnesyl-PP234
with squalene synthase, squalene, lanosterol and nally cholesterol. The ob-235
served decrease in each entity within the network at approximately 20 hours236
is the result of global and local feedbacks within the system. Firstly, the in-237
crease in cholesterol leads, via the negative feedback between cholesterol and238
SREBP-2 transcription of HMGCR mRNA and squalene synthase mRNA,239
to a decrease in the concentration of HMGCR and squalene synthase, re-240
spectively. This globally controlled feedback reduction in the two enzymes241
subsequently means less of the central cascade products are now being synthe-242
sised. This feedback is explored in more detail in Section 7.1. Simultaneously,243
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Figure 2: Numerical solutions to equations (34) to (46) with parameter values detailed
in Table 2. Solutions show the response of HMGCR and squalene synthase mRNA
to initial zero cholesterol concentrations, the subsequent increase in HMGCR and
squalene synthase which allows the synthesis of cascade products geranyl-PP, farnesyl-
PP, squalene, lanosterol and nally cholesterol.
17
and more locally, negative feedbacks from geranyl-PP, farnesyl-PP, lanosterol244
and cholesterol seek to limit the enzymatic action of HMGCR and squalene245
synthase by increasing their rates of degradation. These local feedbacks are246
explored in more detail in Section 9.247
The subsequent decrease in cholesterol levels leads to a small increase in248
HMGCR and squalene synthase mRNA transcription. Eventually the so-249
lutions evolve to reach a steady-state. Solutions of the model show that250
concentrations of both farnesyl-PP and cholesterol are greater than those of251
other cascade products; geranyl-PP, squalene and lanosterol. One reason for252
this could be because farnesyl-PP is a major branch point in the pathway253
and is used (as is cholesterol) in a greater number of cell processes, thus their254
respective concentrations need to be higher. We note that HMGCoA initially255
increases (as a result of its own synthesis) before decreasing to steady-state256
levels due to increased HMGCR levels.257
Direct comparison with experimental values for the concentration of each en-258
tity within the pathway is dicult given a lack of reported values in the lit-259
erature. In the case of HMGCR mRNA we can approximate this via Rudling260
et al. [30] who states there are 30 copies of HMGCR mRNA found in each261
human liver cell under basal conditions. This leads to a concentration of262
3:00 1010 molecules/ml, for which our result of 1:13 1010 molecules/ml is263
very similar. Our concentrations of HMGCR mRNA, HMGCR and choles-264
terol are also in agreement with those previously reported in Bhattacharya265
et al. [2].266
5. Model Analysis267
In this and subsequent sections we undertake a comprehensive analysis of the268
mevalonate pathway model. Given the overall network complexity and di-269
culty in obtaining analytical solutions to the system of governing equations270
we begin with a sensitivity analysis in Section 5.1. Results from this high-271
light enzyme-rate rate limiting steps within the pathway which are explored272
in more detail analytically in Section 6. We consider a simplied model of273
the pathway, containing the key enzyme-substrate reactions and feedbacks274
within the pathway in Section 7, in order to examine the steady-states of the275
system and their stability. Numerical experiments are conducted in Section 8276
to verify our ndings.277
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5.1. Sensitivity analysis278
We conducted a local sensitivity analysis, varying each parameter in turn, up279
to 100-fold above and below the values reported in Table 2. We quantitatively280
measured, primarily, the eect of parameter variation on the steady-state281
cholesterol concentrations (in relation to the unperturbed system) whilst also282
looking for signicant variations in key elements of the pathway, for exam-283
ple steady-state farnesyl-PP concentrations and dierences in the dynamic284
behaviour of each model variable. Varying the model parameters up to 100-285
fold allows us to explore the robustness of the pathway to changes greater286
than those biologically feasible thereby ensuring all possible eects have been287
explored.288
In what follows we present our results by discussing parameters related to289
specic processes within the pathway (e.g. HMGCR synthesis) wherever pos-290
sible. Given their number and to ascertain their eects separately, negative291
feedbacks within the pathway are discussed separately in Sections 7.1 and 9.292
Not all parameters caused a notable change in the system; only those that293
did are discussed here.294
The results of our local sensitivity analysis were subsequently conrmed by
a metabolic control analysis in which the relationship between the system
steady-states and the properties of the individual reactions was explored.
The response coecients were calculated via
R = Rim =
Pm
Ssti
@Ssti
@Pm
;
where R is the matrix of response coecients, Pm is each parameter value295
and Ssti is the corresponding metabolite (mRNA/substrate/enzyme in our296
system) at steady-state.297
5.1.1. HMGCoA synthesis (!)298
The HMGCoA-HMGCR reaction point in the pathway is the rst rate lim-299
iting step in the cascade [34] and HMGCoA is the starting point of all the300
central cascade reactions. Hence decreasing HMGCoA availability 10-fold301
leads to an abundance of enzyme HMGCR (over 300% more) and leads to302
a reduction of over 90% in all cascade products except farnesyl-PP (73%).303
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Increasing the rate of HMGCoA synthesis 10-fold, decreases HMGCR con-304
centrations by almost 100% due to the abundance of HMGCoA, but has only305
a moderate eect on the concentrations of cascade products (around 33%)306
including cholesterol. In all cases farnesyl-PP is more tightly regulated, and307
exhibits a smaller percentage change, than the rest of the cascade products.308
Thus the farnesyl-PP squalene synthase substrate-enzyme reaction appears309
to act as a second rate limiting step in the pathway, lending greater control310
to downstream cholesterol concentrations. This is explored in further detail311
in Section 6.312
5.1.2. Genetic regulation of HMGCR (1, 3, 1 and 3)313
Parameter changes that induce an increase in HMGCR mRNA or HMGCR314
did not greatly aect the pathway. This is because the substrate HMGCoA is315
almost completely utilised and thus cholesterol increases are limited in spite316
of the amount of HMGCR being produced i.e. the binding of HMGCoA317
and HMGCR has reached its upper limit. This combined with the results of318
altering the rate of HMGCoA synthesis !, show there is a careful balance of319
both enzyme HMGCR and substrate HMGCoA in order for cholesterol to be320
produced. If there is an abundance of either enzyme or substrate, the reaction321
will be limited by the lower of the two concentrations without a signicant322
eect on cholesterol concentrations. However, biologically, we would always323
expect the concentration of enzyme to be less than the concentration of324
substrate.325
On the other hand, decreasing the rates of transcription and translation (1,326
3) or increasing the rates of HMGCR mRNA and HMGCR degradation (1327
and 3) has a signicant eect on cholesterol concentrations, as well as de-328
creasing all the other cascade products. For example, decreasing the value of329
1 or 3 by even one order of magnitude causes an 88% decrease in cholesterol330
levels. Increasing the value of 1 or 3 by one order of magnitude has a simi-331
lar eect. Concentrations of HMGCR are, unsurprisingly, decreased leading332
to an accumulation of HMGCoA. Products of the central cascade are all333
decreased by around 88% (farnesyl-PP 68%). The reduction of cholesterol334
upregulates squalene synthase via the local squalene synthase degradation335
feedback shown in Figure 1.336
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5.2. Genetic regulation of squalene synthase (2, 4, 2 and 4)337
Parameter changes that cause an increase in squalene synthase mRNA or338
squalene synthase do not greatly aect the pathway. An abundance in squa-339
lene synthase leads to a signicant decrease in farnesyl-PP, but the increase340
in cholesterol concentrations (as well as those of squalene and lanosterol) is341
only around 7%. Increasing the amount of squalene synthase does have a342
greater eect on cholesterol concentrations than increasing the amount of343
HMGCR, however we again see the balanace of enzyme and substrate limit-344
ing the reaction.345
Parameter changes that cause a decrease in squalene synthase mRNA or346
squalene synthase have less of an eect on concentrations of cholesterol than347
a decrease in HMGCR. For example, decreasing the value of transcription of348
squalene synthase mRNA (2) or translation of squalene (4), by one order of349
magnitude causes a 39% decrease in cholesterol levels. Increasing the value of350
2 (the degradation rate of squalene synthase mRNA) or 4 (the degradation351
rate of squalene synthase) by one order of magnitude has the same eect. In352
each case concentrations of squalene synthase are, unsurprisingly, decreased353
which leads to an accumulation of farnesyl-PP. Products downstream of the354
farnesyl-PP-squalene synthase reaction (bound farnesyl-PP, squalene, lanos-355
terol and cholesterol) are all decreased by around 39%, another indicator of356
a limiting step at this point in the pathway. This decline in cholesterol and357
other cascade product concentrations slightly reduces HMGCR degradation358
(2% change) as expected. We can demonstrate the eect of the HMGCR359
degradation feedbacks by comparing the concentrations between one and360
two orders of magnitude change in 2 and 4, where cholesterol and lanos-361
terol concentrations decrease by 92.6%, HMGCR concentrations increase by362
8%.363
5.2.1. Association and disassociation of HMGCR for HMGCoA and farnesyl-364
PP for squalene (4,  4, 5 and  5)365
Altering the association rates of each of these enzyme and substrate reactions366
has a small eect on cholesterol levels and downstream cascade products.367
We found that decreasing the rate of binding (5) in the squalene synthase-368
farnesyl-PP reaction, has a greater eect on cholesterol and downstream369
cascade product levels than decreasing the binding rate (4) in the HMGCR-370
HMGCoA reaction, again indicating the importance of the squalene synthase-371
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farnesyl-PP rate limiting step. Altering the disassociation rates ( 4 and372
 5) of each reaction has no eect on cholesterol levels or indeed the rest of373
the system.374
5.2.2. Production of geranyl-PP and squalene (5 and 7)375
Decreasing the rate at which either of the enzyme-substrate complexes are376
converted to a product decreases the concentrations of the respective down-377
stream products. Specically decreasing the rate of squalene production, has378
a lesser eect on products downstream of the reaction than decreasing the379
rate at which geranyl-PP is produced. Decreasing either of these rates leads380
to an increase in both substrate concentrations but, counter-intuitively, de-381
creases the concentration of both enzymes. This happens for two reasons;382
rstly the enzymes are held in their bound rather than free forms (shown by383
an increase in bound substrate concentrations). Secondly, increases in each384
substrate concentration ensures that any enzyme synthesised or returned385
from disassociation with the enzyme-substrate complex is quickly bound by386
the excess substrate. Increasing the rate of complex to product conversion387
(5 and 7) has very little eect on downstream cascade products, given they388
are limited by the amount of available substrate (HMGCoA and farnesyl-PP,389
respectively).390
5.2.3. Production of farnesyl-PP and lanosterol (6 and 8)391
Increasing the production rate of farnesyl-PP and lanosterol has very little392
eect on the pathway and cholesterol levels. Interestingly, decreasing the393
production rate of farnesyl-PP has a greater eect on the central cascade394
products than decreasing the production of lanosterol. Decreasing 6 100-395
fold reduces cholesterol concentrations by 22%, reducing the degradation of396
HMGCR and squalene synthase, which increase by 1:5% and 3:4% respec-397
tively.398
5.2.4. Production of cholesterol (9)399
Increasing the rate of production of cholesterol does not greatly aect choles-400
terol concentrations, however decreasing 9 has a small to moderate eect401
on cholesterol levels. However, the changes in lanosterol concentrations as402
a result, have the greatest eect on HMGCR concentrations via the local403
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degradation feedbacks, in comparison to parameter changes that induce an404
increase or reduction of geranyl-PP or farnesyl-PP - the other degradation405
feedbacks on HMGCR.406
5.2.5. Degradation of farnesyl-PP (6)407
Decreasing the degradation rate of farnesyl-PP slightly increases the steady-408
state concentration of cholesterol and other downstream cascade products409
(within 10%). As expected this negatively eects both HMGCR and squalene410
synthase via the degradation feedbacks by a moderate amount in order to411
limit the increase in farnesyl-PP and cholesterol. However, increasing the412
degradation rate of farnesyl-PP by just one order of magnitude impacts the413
downstream cascade signicantly, decreasing the concentrations of squalene,414
lanosterol and cholesterol by 52:4% (33:6% for farnesyl-PP). The decrease in415
cholesterol subsequently up-regulates HMGCR and squalene synthase levels.416
Interestingly, squalene synthase is increased slightly more than HMGCR.417
This could be to counteract the loss of farnesyl-PP through degradation, to418
ensure cholesterol concentrations are maintained.419
5.2.6. Degradation of geranyl-PP and lanosterol (5 and 7)420
Altering the degradation rates of geranyl-PP and lanosterol have very little421
eect on the pathway or steady-state cholesterol levels. Increasing degra-422
dation of geranyl-PP by 100 fold moderately reduces the concentrations of423
the central cacade and slightly upregulates squalene synthase and HMGCR.424
Squalene synthase more so. Increasing the degradation rate of lanosterol by425
100-fold also reduces the concentrations of lanosterol and cholesterol by ap-426
proximately the same amount, however, HMGCR is upregulated more than427
squalene synthase. This is a result of the change in central cascade products428
and the role of the Michaelis-Menten responses aecting the feedbacks to429
HMGCR and squalene synthase, respectively.430
5.2.7. Cholesterol degradation (8)431
Varying the rate of cholesterol degradation greatly eects cholesterol con-432
centrations. As expected the increase in cholesterol concentrations downreg-433
ulates HMGCR and squalene synthase via the local degradation feedbacks,434
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however only by around 1%. Similiarly for decreased cholesterol concentra-435
tions, HMGCR and squalene synthse are upregulated by around 0.1%.436
5.2.8. Genetic binding anities and stoichiometric coecients (1, 2, 3,437
xc, xh and xs)438
Binding anities and stoichiometric coecients involved with the genetic439
regulation of HMGCR and squalene synthase have very little eect on the440
system. Interestingly, reducing parameters involved in genetic regulation of441
HMGCR has a greater eect on the system than those in regulating squalene442
synthase, however these changes would indicate a fraction of a binding site443
which is biologically infeasible. Furthermore, decreasing the value of 3, the444
regulation of HMGCR and squalene synthase by cholesterol has the eect445
of decreasing cholesterol concentrations, signicantly for a 100-fold decrease,446
whilst slightly upregulating HMGCR and squalene synthase.447
5.2.9. Sensitivity analysis summary448
Local sensitivity analysis has highlighted that a decrease in HMGCR (the449
rst rate limiting step in the pathway), caused by parameters linked with450
its genetic regulation, signicantly decreases steady-state cholesterol concen-451
trations. However, increases in products linked with genetic regulation of452
HMGCR do not have a signicant impact on steady-state cholesterol con-453
centrations, due to the occurence of the second rate limiting step between454
squalene synthase and farnesyl-PP. The eect of decreasing products linked455
with genetic regulation of squalene synthase is not as signicant as those456
linked with regulation of HMGCR.457
An increase in products prior to the reaction of farnesyl-PP with squalene458
synthase rarely causes a signicant change in cholesterol levels (the excep-459
tion being a decrease in 5 reducing cholesterol concentrations signicantly),460
whilst the degradation of farnesyl-PP has a high eect on downstream prod-461
uct concentrations. We found that, with the exception of decreasing 5, the462
rates of geranyl-PP and squalene formation, from the two enzyme-substrate463
reactions within the pathway, have a moderate eect on limiting downstream464
products formed in the pathway. In contrast, altering the rates of geranyl-465
PP and lanosterol degradation have little impact on the pathway. Cellular466
cholesterol concentrations are very sensitive to changes in the rate of choles-467
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terol esterication (degradation) without much interruption to the rest of the468
pathway.469
Our results, as summarised in Table 3, demonstrate that the two rate limiting470
steps of HMGCR and HMGCoA and farnesyl-PP and squalene synthase,471
coupled with the negative feedback between cholesterol and SREBP-2, act472
as core regulators of products within the central cascade. The HMGCoA473
and HMGCR rate limiting step is aimed at controlling production of central474
cascade substrates, whilst that of farnesyl and squalene synthase appears475
two-fold; it acts to control the levels of lanosterol and ultimately cholesterol476
produced, but also regulate those of farnesyl-PP, given its role in other cell477
signalling pathways. Whilst the enzyme rate limiting step of HMGCR and478
HMGCoA follows one-to-one stoichometry, this diers for squalene synthase479
and farnesyl-PP; two molecules of farnesyl-PP reversibly bind to squalene480
synthase, to produce one molecule of complex bound farnesyl-PP. The eect481
of this is investigated further in Section 6.482
Table 3: Sensitivity analysis summary. Results here indicate up to a 10% (denoted
`+' or `-'), 10-50% (`++/- -'), greater than 50% (`+++/- - -') variation or no change
(`NC') in the steady-state cholesterol levels for the parameterisation detailed in Table 1
for 10-fold parameter variations.
Change Made Parameters Involved Eect on Cholesterol
Increased HMGCoA ! ++
Decreased HMGCoA ! |
Increased HMGCR 1; 3; 1; 3 NC
Decreased HMGCR 1; 3; 1; 3 - - -
Increased Squalene synthase 2; 4; 2; 4 +
Decreased Squalene Synthase 2; 4; 2; 4 - -
Increased Association of Enzymes 4; 5 +
Decreased Association of Enzymes 4; 5 - -
Dissociation of Enzymes  4;  5 NC
Increased Product formation 5; 7 NC
Decreased Product formation 5 - - -
Decreased Product formation 7 - -
Increased degrataion of FPP 6 - - -
Decreased degradation of FPP 6 +
Increased degradation 5; 7 -
Decreased degradation 5; 7 NC
Degradation of cholesterol 8 + + + / - - -
Stoichiometric coecients xc; xh; xs NC
Genetic binding anities K1;K2 NC
Increased genetic binding anity K3 NC
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Decreased genetic binding anity K3 -
Half Max degradation binding K6;K7;K8;K9;K10 NC
Increased Product formation 6; 8 NC
Decreased Product formation 6 -
Decreased Product formation 8 NC
Increased Product formation 9 NC
Decreased Product formation 9 -
6. The farnesyl-PP - squalene synthase rate limiting step483
Sensitivity analysis of the previous section has revealed evidence of two rate484
limiting steps working together to regulate homeostatic cholesterol levels.485
The rst is that of the well documented HMGCR HMGCoA reaction, whilst486
the second involves farnesyl-PP reacting with squalene synthase. Here we487
investigate the role of the latter reaction, in particular the role of the stoi-488
chometry between farnesyl-PP and squalene synthase in eecting the creation489
of products downstream of this reaction. In order to do so we consider a sim-490
plied version of this part of the network as given by the reaction stated in491
equation (47).492
Ua Vb???yu ???yv
2A + B
ab   *)  
 ab
Cx
p
    ! Pt + B:???yp1

(47)
In this case we have employed A to represent farnesyl-PP, B squalene syn-493
thase, Cx the enzyme-substrate complex, Pt squalene and Ua and Vb the inux494
of substrate and enzyme respectively. For simplicity we assume a constant495
source of enzyme Ua and substrate Vb, at rates u and v, respectively, and we496
have removed the eect of the feedback of cholesterol onto squalene synthase497
degradation. Here ab and  ab represent the binding and unbinding, respec-498
tively, of A and B, p is the rate at which the product is formed and nally499
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the degradation of P is represented by p1. We observe that A;B;Cx; Pt  0500
is required for biologically feasible solutions.501
Applying the law of mass action to equation (47) leads to502
da
dt
=  2a2bab + 2cx ab + uau; (48)
db
dt
=  a2bab + cx ab + vbv + cxp; (49)
dcx
dt
= a2bab   cx ab   cxp; (50)
dpt
dt
= cxp   ptp1; (51)
with the initial conditions503
a(0) = a0; b(0) = b0; cx(0) = 0; pt(0) = 0:
We observe that the addition of equations (49) and (50) leads to
da
dt
+
db
dt
= vbv;
which for large time becomes504
b+ cx  vbvt: (52)
This suggests that a, b, cx and subsequently pt follow solutions of the form505
a  a0t; b  b0t; cx  cx0t and pt  pt0t: (53)
Substitution of these solution approximations into equations (48)-(51) leads506
to507
a  Kt 1=2; b  vbpt; cx  uau
2p
and pt  uau
2p1
: (54)
for which we have the results a ! 0, b ! 1 for nite cx and pt. This508
result demonstrates that the substrate farnesyl-PP tends to zero, squalene509
synthase grows unboundedly in time whilst the complex (bound farnesyl-PP)510
and product (squalene) remain bounded for any degree of inux.511
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From this analysis we can conclude that the rate limiting interaction of squa-512
lene synthase and farnesyl-PP would ensure product formation (squalene) is513
nite and bounded regardless of whether the substrate (farnesyl-PP) or en-514
zyme (squalene synthase) concentrations are bounded. Furthermore, if the515
levels of squalene are bounded the subsequent products i.e. lanosterol and516
cholesterol will also be bounded. Thus the mechanism has the downstream517
eect of ensuring cholesterol levels do not become excessive and alleviates518
the likelihood of biosynthetic cytotoxicity.519
7. Steady-state stability analysis520
The recent work of Bhattacharya et al. [2] demonstrated that a nonlinear521
ODE model describing cholesterol biosynthesis via HMGCR mRNA tran-522
scription and subsequent HMGCR translation was monostable. The meval-523
onate pathway examined here is essentially an extension of that model which524
incorporates further pathway details between HMGCR and cholesterol syn-525
thesis. The increased complexity raises the question as to whether the system526
exhibits a single real stable steady-state. In this section we utilise a reduction527
of the full model derived in Section 3 to investigatve this.528
7.1. Model reduction529
Given the complexity of the governing equations of the full pathway model530
system (equations (34)-(45)) we begin by simplifying the full pathway (hence-531
forth known as the full model) of Figure 1 by that shown in Figure 3. Here532
the core product forming and branching points in the pathway have been533
retained such that w represents SREBP-2, u HMGCR, v squalene synthase,534
x HMGCoA, y farnesyl-PP and z cholesterol. Here x is produced at a rate535
A and the negative feedbacks between each relevant component have been536
included. We further assume that the cholesterol-SREBP-2 negative feed-537
back is the fastest acting process in this reduced network, followed by the538
synthesis of HMGCR and squalene synthase, which occurs an order of mag-539
nitude slower. Subsequently the formation of x, y and z are assumed to be540
the slowest in the pathway. Finally, x, y and z decay proportional to their541
respective concentrations.542
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Figure 3: A model reduction of the mevalonate pathway which incorporates the key
enzyme and substrate synthesis processes and branch points, along with their re-
spective feedbacks. Here w represents SREBP-2, u HMGCR, v squalene synthase, x
HMGCoA, y farnesyl-PP and z cholesterol, where x is produced at a rate A. It is
assumed, as with the full-pathway model, that x, y and z decay proportional to their
respective concentrations (not shown here).
Applying these assumptions and the law of mass action to the reduced path-543
way of Figure 3 leads to the following non-dimensional system of equations544
_x = A  r1xu  r1x; (55)
_y = r1xxu  r2yv   r2y; (56)
_z = r2yyv   r3z; (57)
 _u = r3w   r4u

uz
z
r1 + z
+ uy
y
r2 + y
+ 1

; (58)
 _v = r4w   r5v

vz
z
r3 + z
+ 1

; (59)
2 _w =
r1
r4 + zn1
  r6w; (60)
with the initial conditions545
x = 1; y = 1; z = 1; u = 1; v = 1 and w = 1: (61)
Here  represents a small parameter and the remaining model parameters are546
given by r1 which represents the rate at which x produces y, r2 is the rate547
at which y produces z, r3 the rate at which u is transcribed, r4 the rate548
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at which v is transcribed, x and y are non-dimensional ratios representing549
the initial dimensional concentrations of x and y, and y and z, respectively550
and r1 that rate at which w is produced. The eective binding sites of551
cholesterol on SREBP-2 is represented by n1 and r1;2;3;4;5;6 represent the552
rate of degradation of x; y; z; u; v and w, respectively. Finally, r1;2;3;4 are the553
Michaelis-Menten constants associated with the feedback of z on the rate554
of u degradation, y on that of u degradation, z on v degradation and z on555
w inhibition, respectively and uz, uy and vz are dimensionless constants556
respectively representing their eect. As with the full model of Section 3557
and for the sake of simplicity we henceforth assume, unless otherwise stated,558
uz = 1 = uy = vz.559
Taking the O(1) expansion of equations (55)-(60) leads to560
_x = A  ~r1x
(r4 + zn1)

z
r1+z
+ y
r2+y
+ 1
   r1x; (62)
_y =
~r1xx
(r4 + zn1)

z
r1+z
+ y
r2+y
+ 1
   ~r2y
(r4 + zn1)

z
r3+z
+ 1

 r2y; (63)
_z =
~r2yy
(r4 + zn1)

z
r3+z
+ 1
   r3z; (64)
where561
~r1 =
r1r3r1
r4r6
and ~r2 =
r2r4r1
r5r6
: (65)
Assuming the concentrations of cholesterol and farnesyl-PP are in excess562
and the rates of anity of cholesterol for HMGCR and squalene synthase563
(kr1 and kr3) and farnesyl-PP for HMGCR are signicantly high such that564
kr1; kr3  z and kr2  y leads to kr1 + z  z, kr2 + y  y and kr3 + z  z.565
Thus566
_x = A  rr1x
r4 + zn1
  r1x = f(x; y; z); (66)
_y =
rr1xx
r4 + zn1
  rr2y
r4 + zn1
  r2y = g(x; y; z); (67)
_z =
rr2yy
r4 + zn1
  r3z = h(x; y; z); (68)
where rr1 =
1
3
~r1 and rr2 =
1
2
~r2.567
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7.2. Steady-state stability568
Solving for the steady-states (x; y; z) of equations (66)-(68) leads to the
polynomial (recalling that n1 is an integer)
z2n1+1(r1r2r3) + z
n1+1(r1r3rr2 + 2r1r2r3r4 + r2r3rr1)
+ z(r2r3rr1r4 + r1r2r3
2
r4 + r1r3rr2r4 + r3rr1rr2) 
Arr1rr2xy = 0; (69)
which via Descartes' rule of signs [27] has only one positive root z. From569
(66) and (67) it follows that the corresponding x and y are also positive.570
Now the Jacobian of equations (66)-(68) is given by571
J =
0BBBBB@
 rr1
r4+zn1
  r1 0 n1rr1xzn1 1(r4+zn1 )2
rr1x
r4+zn1
 rr2
r4+zn1
  r2  n1rr1xxzn1 1(r4+zn1 )2 +
n1rr2yzn1 1
(r4+zn1 )2
0 rr2y
r4+zn1
 n1rr2yyzn1 1
(r4+zn1 )2
  r3
1CCCCCA ;
which allows us to determine the characteristic equation572
3 + a1
2 + a2+ a3 = 0;
where573
a1 =  (fx + gy + hz); a2 = fx(gy + hz) + gyhz   gzhy
and a3 =  (fx(gyhz   gzhy) + fzgxhy): (70)
Now for (x; y; z) to be stable we require Re() < 0 meaning that the574
following Routh{Hurwitz conditions [27] must hold575
a1 > 0; a3 > 0 and a1a2   a3 > 0: (71)
It is easily seen that fx; gy; hz < 0 (diagonal entries of J) whilst fz; gx; hy > 0.576
The remaining non-zero term of the Jacobian is577
gz =  

n1z
n1 1
r4 + zn1

rr1xx
r4 + zn1
  rr2y
r4 + zn1

:
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Both sets of brackets are clearly positive at steady{state (the second set from578
(67)) and so we have gz < 0 at the steady{state.579
Using the signs of the Jacobian entries at steady state immediately gives580
a1 > 0 and, with a little work we can readily use them to deduce that581
a1a2  a3 > 0. In order to show the remaining required inequality we cannot582
use the signs of the Jacobian entries alone. Instead we rst simplify notation583
by writing584
1 =
 rr1
r4+zn1
; 2 =
 rr2
r4 + zn1
;
1 =
n1rr1xzn1 1
(r4+zn1 )2
; 2 =
n1rr2yz
n1 1
(r4 + zn1)2
;
noting that each of these is non-negative. The Jacobian can then be written585
as586
J =
0BBBB@
 1   r1 0 1
1x  2   r2  1x + 2
0 2y  2y   r3
1CCCCA ;
and a3 as587
a3 = (1 + r1) ((2 + r2)(2y + r3) + 2y(1x(1x   2))
 11x2y
= (1 + r1) (2r3 + 2yr2 + r2r3) + r121xy :
Since each symbol is non-negative we immediately have that a3 > 0 as re-588
quired. Thus (x; y; z) is stable.589
In order to provide a check of the stability obtained from the reduced model,590
we numerically calculated the Jacobian for the full model system using the591
parameter values detailed in Table 2. All eigenvalues are found to be negative592
or approximately zero, for a range of initial conditions.593
8. Periodic solutions594
The results of Section 7 have demonstrated that the mevalonate pathway595
exhibits one real steady-state. Both this model and that of Bhattacharya et596
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al. [2] include the negative regulation of SREBP-2 by cholesterol. In the case597
of the three variable model analysed by Bhattacharya and colleagues, they598
demonstrated that the system could exhibit periodic behaviour under certain599
model parameterisations. As such we now investigate numerically whether it600
is possible for the mevalonate pathway model to exhibit oscillatory solutions.601
Our investigations focused on the parameters 1, 3, xc and 8 given they602
are directly involved in the cholesterol-SREBP-2 feedback, are parameters603
for which periodic behaviour was shown in [2], and the results of varying all604
other model parameters in Section 5.1 produced no periodic behaviour.605
Local sensitivity analysis of 1, 2, 3, xc and 8 revealed the presence of606
periodic (damped or undamped) behaviour within the system, an example607
of which is shown in Figure 4. The presence of oscillatory behaviour for608
other parameter values showed comparable results. We note the increase in609
concentration of HMGCoA in Figure 4 is a result of the choice in w made to610
demonstrate the existence of oscillatory solutions. We sought to numerically611
investigate further the likelihood of a Hopf bifurication within the mevalonate612
pathway, as a result of this feedback, and undertook a phase space analysis613
using MATLAB'S ode15s solver and the plot3 function. We found that the614
system exhibits an unstable xed point surrounded by a stable limit cycle615
and thus appears to undergo a supercritical Hopf bifurcation (results not616
shown). This was found to be the case when considering the HMGCRmRNA,617
HMGCR and cholesterol phase space as well as that for squalene synthase618
mRNA, squalene and cholesterol.619
These results indicate that the full mevalonate pathway model is able to pro-620
duce periodic behaviour, similar to that related to more simplied networks621
within it (e.g. HMGCR mRNA, HMGCR and cholesterol), so long as the622
global scale negative feedback between cholesterol and SREBP-2 is present.623
9. Investigating feedbacks624
In this section we consider how feedbacks within the mevalonate pathway625
contribute to the robust control of cholesterol concentrations. Whilst in pre-626
vious sections we have focused on the role of the global cholesterol-SREBP-627
2 negative feedback, here we consider the eect of geranyl-PP, farnesyl-PP,628
lanosterol and cholesterol regulating the degradation of HMGCR, and choles-629
terol regulating the degradation of squalene synthase, respectively.630
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Figure 4: Solutions to the system of equations (34) to (46) for which periodic be-
haviour is exhibited. In this case 1= 1 10 12, 2= 1 10 12, 3= 3.74 10 4, 8
= 0.1, with all other parameters as in Table 2.
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Given the complexity of the full pathway we began by considering the reduced631
model shown in Figure 3. This allowed for initial examination of the eect of632
the feedbacks on the core elements of the network (e.g. rate limiting steps and633
core products), rather than each individual entity in the full pathway. We634
identied each feedback in Figure 3 as: (1) z ! u (cholesterol to HMGCR);635
(2) y ! u (farnesyl-PP to HMGCR); and (3) z ! v (cholesterol to squalene636
synthase).637
We undertook numerical simulations of equations (55) - (60) using the MAT-638
LAB solver ode15s, assuming  = 0:1 under the eight scenarios detailed in639
Table 4; when all feedbacks were present, no feedbacks were present, each640
feedback acted independently and pair-wise. We recorded the dierence in641
steady-state cholesterol concentration, measured as a percentage relative to642
when all feedbacks were present, in Table 4.643
The results in Table 4 clearly show that for fewer feedbacks steady-state644
cholesterol concentrations increase. When no feedbacks are present, choles-645
terol levels increase by 27.4% in comparison to when all feedbacks are present.646
Individually, the feedback from farnesyl-PP onto HMGCR has the great-647
est eect on regulating cholesterol levels, whereas those from cholesterol to648
HMGCR and squalene synthase have the least similar eect. Interestingly649
our results demonstrate that the feedbacks between cholesterol and HMGCR650
and squalene synthase, respectively, together have just as tight a control on651
cholesterol as that of the feedback from farnesyl-PP to HMGCR. The re-652
sults of Table 4 also show that local positive feedbacks aecting the rates of653
HMGCR and squalene synthase degradation act together with the two rate654
limiting steps in which they are respectively involved, to tightly regulate the655
concentration of cholesterol. Importantly, they are able to do so more di-656
rectly and thus more rapidly, given less regulatory steps are involved, than657
via the feedback between cholesterol and SREBP-2.658
To test the robustness of the feedback responses, specically the transient659
concentration of cholesterol, we introduced a transient inux of cholesterol,660
B in to z such that661
B =
(
1; for 0:10  t  0:15;
0 otherwise:
(72)
under diering feedback scenarios.662
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Table 4: The percentage relative dierence in steady-state cholesterol concentration
for when dierent feedbacks are included compared to when all three feedbacks are
in play for the reduced model of Figure 3. In the case of comparing feedbacks either
individually or pairwise, the other feedbacks were turned o. Here: (1) z ! u (choles-
terol to HMGCR); (2) y ! u (intermediate substrates to HMGCR); and (3) z ! v
(cholesterol to squalene synthase) as, dened in Figure 3.
Scenario Corresponding weighting Percentage increase in
parameters steady-state cholesterol levels.
No feedbacks uz = 0 = uy = vz: 27.4%
(1) uz = 1; uy = 0 = vz. 12.6%
(2) uz = 0; uy = 1; vz = 0. 1.6%
(3) uz = 0 = uy; vz = 1. 12.9%
(1); (2) uz = 1 = uy; vz = 0. 12.6%
(1); (3) uz = 1; uy = 0; vz = 1. 1.6%
(2); (3) uz = 0; uy = 1 = vz. 10.3%
Figure 5: The impact of feedbacks on the reduced model of Figure 3 for the case where
z (cholesterol) is increased for 0:10 < t < 0:15. Equations (55)-(60) were solved for
all parameter set equal to one with the exception of  = 0:1. Solutions were allowed
to reach steady-state before the eect of turning each feedback o was investigated.
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Figure 5 demonstrates that each of the feedbacks tightly regulate the concen-663
trations of x, y and z and that varying combinations of them did not alter the664
overall transient behaviour. Additionally in scenarios where feedback (3) was665
turned o, levels of y (farnesyl-PP) were very low as more squalene synthase666
is available to bind with farnesyl-PP to form squalene. This coupled with667
the analysis undertaken in Section 6 showing if the concentration of squalene668
synthase grows unbounded the rate limiting step between it and farnesyl-PP669
acts to control the downstream concentrations of lanosterol and subsequently670
cholesterol, demonstrates these two processes act together locally to tightly671
regulate cholesterol levels in this section of the pathway.672
We undertook the same analysis of each feedback on the full model of the673
pathway, equations (34) to (46). We inhibited the feedbacks from: (1) choles-674
terol to HMGCR degradation; (2) farnesyl-PP to HMGCR degradation; and675
(3) cholesterol to squalene synthase degradation. We again conducted the676
same eight scenarios detailed in Table 4 and found all scenarios show the same677
transient behaviour in good agreement with the reduced model. The only678
notable change was were switching feedback (2) o led to slightly higher lev-679
els of HMGCR. This dierence was not seen when feedback (3) was switched680
on concurrently to feedback (2).681
10. CYP51 inhibition682
So far we have demonstrated that cholesterol biosynthesis via the mevalonate683
pathway is a tightly regulated process; a result of two enzymatic rate limiting684
steps coupled with local and global feedbacks within the signalling network.685
In this section we show how these elements integrate together to ensure a686
robust network response to the eect of the fungicide agent CYP51. CYP51687
is known to inhibit post lanosterol production processes and is used in crop688
protection as an anti-fungal agent. It acts by reducing cholesterol concen-689
trations within the cell, thereby compromising cell wall integrity, ultimately690
leading to cell death. Concerns exist that this inhibition is likely to lead to691
increases in farnesyl-PP levels, thereby inducing unwanted side-eects within692
other cell signalling cascades who share cross-talk with farnesyl-PP.693
To investigate the eect of CYP51 inhibition on the pathway we rst ran the694
system of equations (34) to (46) to steady-state. Taking this as our starting695
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Figure 6: The eect of CYP51 inhibition on equations (34) to (46). Here 9 = 0 at
t = 5 hours for 2 hours with 3=0.075, to simulate CYP51 inhibition as described
by equation (73). Cholesterol concentrations decline which leads to a decrease in
HMGCR levels as a result of the feedback between cholesterol and SREBP-2. Hence
concentrations of geranyl-PP, farnesyl-PP and squalene all decline. All concentrations
return to steady-state after CYP51 inhibition stops.
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point we then simulated the eect of CYP51 inhibitors by letting696
9 =
(
0; for 5  t  7;
3:61 102 otherwise: (73)
Results are shown in Figure 6. We see that CYP51 inhibition leads to a697
sharp increase in lanosterol and decline in cholesterol concentrations. Here698
we would expect an increase in HMGCR concentrations due to the rise in699
HMGCR mRNA, however the sharp increase in lanosterol concentration700
causes the degradation of HMGCR to be up-regulated, and so its concen-701
tration subsequently declines. The reduction in HMGCR thus leads to a702
decline in the central cascade products of geranyl-PP, farnesyl-PP and squa-703
lene. As a result we see that the change in these central cascade products is704
limited and that faresyl-PP levels actually reduce when production of choles-705
terol from lanosterol is inhibited. We note that an increase in inhibition of706
SREBP-2 by cholesterol (3 = 0:075) was required in order to observe a707
response in HMGCR mRNA and squalene synthase mRNA.708
11. Summary and conclusions709
We have formulated, parameterised and analysed a nonlinear ODE model710
of the mevalonate cholesterol biosynthesis pathway. Our results show that711
the pathway tightly regulates steady-state and transient cholesterol levels via712
two rate limiting steps, internal local positive feedbacks aecting the rate of713
degradation of certain products within the pathway and a global negative714
feedback between cholesterol and SREBP-2.715
A local sensitivity analysis of the model revealed a number of important reg-716
ulatory points within the pathway. It highlighted that decreases in HMGCR717
levels has the greatest impact on downstream cholesterol levels either via718
variation in transcription or translation rates or the rate of HMGCR mRNA719
or HMGCR degradation. Increasing products prior to farnesyl-PP interact-720
ing with squalene synthase has a more signicant eect on cholesterol levels721
in contrast to those after the reaction, the rates at which geranyl-PP and722
squalene are formed have the most signicant eect. Altering the rate of723
cholesterol esterication has a signicant impact on HMGCR and squalene724
synthase levels via the cholesterol SREBP-2 negative feedback loop.725
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Our sensitivity analysis also revealed the importance of the rate limiting en-726
zyme substrate reactions of HMGCoA with HMGCR and farnesyl-PP with727
squalene synthase, the latter augmented by separate analytical analysis of the728
farnesyl-PP squalene synthase rate limiting step. The HMGCR-HMGCoA729
reaction was found to be an important upstream regulator of all main path-730
way products. That of farnesyl-PP and squalene synthase was found to731
be important in not only regulating downstream production of squalene,732
lanosterol and thus cholesterol, but in ensuring their levels did not increase733
signicantly if levels of farnesyl-PP and squalene synthase did.734
Analysis of a reduced model of the full pathway, which captured the main735
products and interactions between them, demonstrated that the system ex-736
hibits one real stable steady-state. The global feedback between cholesterol737
and SREBP-2 leads to monotonic, oscillatory and damped oscillatory be-738
haviour, which agrees with the simplied HMGCR cholesterol regulatory739
model of [2]. This result shows that the feedback between cholesterol and740
SREBP-2 acts to globally regulate the dynamic pathway behaviour. This741
is in contrast to internal positive feedbacks between geranyl-PP, farnesylPP,742
lanosterol and the degradation of HMGCR and squalene synthase which our743
analysis demonstrated act directly within the pathway to tightly regulate744
overall cholesterol concentrations.745
It is clear that feedbacks in the pathway act to control the dynamical re-746
sponse, enzyme concentrations and hence the concentration of cholesterol.747
The cholesterol-SREBP-2 feedback allows for cholesterol regulation of its own748
production over a longer timescale than those from geranyl-PP, farnesyl-PP,749
lanosterol and cholesterol to HMGCR and cholesterol to squalene synthase;750
which respond directly within the pathway to any variation in cholesterol lev-751
els. These direct responses alleviate the eect of further reactions in delaying752
the reduction of the entity they are targeting in the pathway.753
Further evidence of the system's robust network control via the integration754
of two rate limiting steps and feedbacks was shown in the case of CYP51755
inhibition. Simulations of CYP51 inhibition show the network response pre-756
vents cytotoxic build up of central cascade products geranyl-PP, squalene and757
farnesyl-PP. This is important since increased farnesyl-PP levels are linked758
with several other signalling pathways and excessive amounts are thought759
to cause tumours. In this way we have shown that CYP51 inhibitors would760
have little eect on farnesyl-PP concentrations in the mevalonate pathway.761
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Given the importance of cholesterol synthesis in maintaining the integrity of762
cell function for many cellular phenotypes, the results of the work here are in763
many ways unsurprising. Cholesterol levels need to be tightly regulated, both764
in response to internal cellular variations and external factors, e.g. disease or765
dietary factors. Our work here has clearly demonstrated that the pathway is766
robustly designed and includes a number of `fail safe' type mechanisms in the767
form of regulatory feedbacks and rate limiting steps which act in concert to768
provide a robust regulatory system. These results are in agreement with the769
work of August et al. [1] and Morgan et al. [25], who both demonstrated that770
the cholesterol biosynthesis aspects of their models were robust to parameter771
variation. The design of the network ensures that the integrity of cholesterol772
levels is not greatly compromised, should one or more of these mechanisms773
fail, thus ensuring cell survival is maintained.774
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Appendix A. Biochemical reaction details781
In order to formulate a mathematical model of the interactions shown in782
Figure 1 we rst consider the biochemical details of each reaction. The783
binding of SREBP-2 to HMGCR DNA and subsequent mRNA and protein784
formation is governed by785
Gh + xhS
1  *) 
 1
Sbh
1    ! Mh
3    ! Hr; (A.1)
where HMGCR free DNA is represented byGh, S is SREBP-2, Sbh is SREBP-786
2 bound to the DNA, Mh is HMGCR mRNA and Hr is HMGCR. The787
constant reaction rates 1 and  1 represent the binding and unbinding of788
SREBP-2 and DNA protein respectively, 1 is the rate of transcription of789
HMGCR mRNA and 3 is the rate of HMGCR translation. Finally xh is the790
number of binding sites on the DNA that SREBP-2 must bind to.791
Binding of SREBP-2 to squalene synthase DNA and subsequent mRNA and792
protein formation is governed by793
Gss + xsS
2  *) 
 2
Sbss
2    ! Mss
4    ! Ss; (A.2)
where free DNA binding sites responsible for squalene synthase synthesis is794
represented by Gss, Sbss is SREBP-2 bound to the DNA, Mss is squalene795
synthase mRNA and Ss is squalene synthase. The constant reaction rates796
2 and  2 represent the binding and unbinding of SREBP-2 and DNA re-797
spectively, 2 is the rate of transcription of mRNA responsible for squalene798
synthase and 4 is the rate of translation of squalene synthase from mRNA.799
Finally xs is the number of binding sites on the DNA that SREBP-2 must800
bind to.801
Binding of HMGCR and HMGCoA and subsequent production of geranyl-PP802
and farnesyl-PP is governed by803
Hr +Hc
4  *) 
 4
Hb
5    ! Gpp + Hr;
6
???y
Fpp
(A.3)
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where free HMGCoA is represented by Hc, Hb is HMGCR bound to HMG-804
CoA, Gpp is geranyl-PP and Fpp is farnesyl-PP. The constant reaction rates805
4 and  4 represent binding and unbinding of HMGCR and HMGCoA re-806
spectively, 5 is the rate of production of geranyl-PP and 6 is the rate of807
production of farnesyl-PP.808
Two molecules of farnesyl-PP bind to one molecule of squalene synthase for809
the subsequent production of squalene, lanosterol and cholesterol such that810
2Fpp + Ss
5  *) 
 5
Fbpp
7    ! Sq + Ss
8
???y
L
9    ! C;
(A.4)
where bound farnesyl-PP and squalene synthase is represented by Fbpp, Sq is811
squalene, L is lanosterol and C is cholesterol. The constant reaction rates 5812
and  5 denote binding and unbinding of squalene synthase and farnesyl-PP813
respectively, 7 is the rate of squalene production, 8 is the rate of lanosterol814
production 9 that of cholesterol.815
The negative regulation of SREBP-2 by cholesterol is governed by816
xcC + S
3  *) 
 3
Cb; (A.5)
where bound cholesterol and SREBP-2 is represented by Cb, the constant817
reaction rates 3 and  3 represent the binding and unbinding of cholesterol818
and SREBP-2, respectively. Finally xc is the number of binding sites that819
must be occupied by cholesterol on SREBP-2 to inactivate SREBP-2.820
Each degradation process is described by821
Mh
1    ! ; Mss
2    ! ; Hr
3    ! ; Ss
4    ! ;
Gpp
5    ! ; Fpp
6    ! ; L
7    ! ; C
8    ! ;
(A.6)
where i (i 2 [1; :::; 8]) are the rates of degradation of each mRNA, protein822
and enzyme, respectively.823
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Appendix B. Model reduction824
We begin by observing three conservation relations. Firstly, the total amount825
of DNA within a cell remains constant such that826
gh + sbh = gh0 and gss + sbss = gss0; (B.1)
which are formed from the addition and integration (with respect to time)827
of equations (1) and (4) , and (2) and (5), respectively.828
The total amount of SREBP-2 in a cell is also constant which similarly gives829
s+ cb = s0; (B.2)
using equations (3) and (18).830
We assume the following reactions occur on a faster timescale than others in
the signalling cascade and as such invoke the quasi-steady-state approxima-
tion. We assume DNA-transcription factor binding is rapid [20, 2] such that
from equation (4)
1s
xh(gh0   sbh)   1sbh  0;
where we have substituted for gh using the rst conservation relationship in831
equation (B.1). This result can be re-arranged for sbh to give832
sbh  gh0s
xh
sxh + Kxh1
; (B.3)
with K1 =

 1
1
 1
xh .833
Using the second conservation relationship in equation (B.1) and applying834
the same assumption to equation (5) yields835
sbss  gss0s
xs
sxs + Kxs2
; (B.4)
with K2 =

 2
2
 1
xs
.836
Finally we assume that cholesterol-SREBP-2 binding is also rapid such that837
from equation (3)838
s 
Kxc3 s0
cxc + Kxc3
=
s0
1 + ( cK3 )
xc
; (B.5)
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with K3 =

 3
3
 1
xc
. This relationship can subsequently be used to express839
sbh and sbss in terms of c.840
Using the results of equations (B.3), (B.4) and (B.5) we can simplify equa-841
tions (6) and (7) to842
d mh
dt
=
1
1 +

K1(1+(
c
K3
)xc )
s0
xh   1 mh; (B.6)
and843
d mss
dt
=
2
1 +

K2(1+(
c
K3
)xc)
s0
xs   2 mss; (B.7)
where 1 = 1gh0 and 

2 = 2gss0.844
Equation (31) is derived from equations (3), (4), (5) and (17), respectively,
such that
d
dt
(s+ xhsbh + xssbss   c=xc) = 9
l   8c
xc
which leads to
(1  xc(s0 + xhs0bh + xss0bss))
dc
dt
= 9l   8c;
via the chain rule, where 0 denotes dierentiation with respect to c such that845
from (B.5), (B.3) and (B.4) we have846
ds
dc
=
 s0xc

c
K3
xc
c

1 +

c
K3
xc2 ; (B.8)
847
dsbh
dc
=
dsbh
ds
ds
dc
=
xhgh0 K
xh
1 s
xh 1
(sxh + Kxh1 )
2
ds
dc
(B.9)
and848
dsbss
dc
=
dsbss
ds
ds
dc
=
xsgss0 K
xs
2 s
xs 1
(sxs + Kxs2 )
2
ds
dc
; (B.10)
respectively. Here gh0 and gss0 are the total concentration of HMGCR and849
squalene synthase DNA, respectively, in a cell.850
45
Appendix C. Parameter details851
In this section we detail, where relevant, calculations used to estimate the852
parameters detailed in Table 1.853
mh0 - Initial concentration of HMGCR mRNA: Ruddling et al. [30]854
details copy numbers of mRNA found in human liver cells under basal con-855
ditions. So we take a value of 30 copies of HMGCR mRNA per cell i.e. per856
10 9 ml. So857
30 molecules
1 10 9ml = 3:0 10
10 molecules/ml:
This value was then rened using local sensitivity analysis to give mh0 =858
3:0 109 molecules/ml.859
mss0 - Initial concentration of squalene synthase mRNA: Ruddling860
et al. [30] details copy numbers of mRNA found in human liver cells under861
basal conditions. So we take a value of 30 copies of squalene synthase mRNA862
per cell i.e. per 10 9 ml. So863
30 molecules
1 10 9ml = 3:0 10
10molecules/ml:
This value was then rened using local sensitivity analysis to give mss0 =864
3:0 109 molecules/ml.865
ssT - Total concentration of squalene synthase: One liver cell contains866
300pg/cell protein and has a volume of 10 9 ml. Bruenger and Rilling [5]867
state there are 4.2 nmol of squalene synthase per gram of wet tissue such868
that869
4:2 10 9mol/g tissue 6:022 1023 molecules/mol
which gives870
2:53 1015molecules /g 1:00 10 12
10 9ml
= 7:59 1014 molecules/ml.
hcT - Total concentration of HMGCoA: One liver cell contains approxi-871
mately 300pg/cell protein and has volume 10 9ml/cell. The molecular weight872
of HMGCoA is 199:659 g/mol according to human metabolic database [38].873
Then we know874
300 10 12g
199:659g/mol
= 3:29 10 13mol/cell:
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So we have, per cell, 3:2910 13mol=10 9ml = 3:9210 4 mol/ml. Applying875
Avagadro's number we can nd the number of molecules per ml876
3:9210 4 mol/ml 6:0221023 molecules/mol = 1:981020 molecules/ml:
Segel (1993) [33] states a cell contains an average of 1000 enzymes, so we have877
9:04 1014 molecules/ml. This value was then rened using local sensitivity878
analysis to give hcT = 1:98 1015 molecules/ml.879
gh0, gss0 - HMGCR and squalene synthase gene concentration: The880
molecular weight of the HMGCR gene is 97,476 Da [41], whilst that of the881
human genome is 2 1012Da [42]. The total quantity of DNA in a cell882
weighs 7pg, such that that of HMGCR is 3.4110 7pg. Observing that 1 Da883
is equivalent to 1g/mol and assuming the volume of a cell is 1 nml, we have884
3:41 10 7 pg 6:023 1023 molecules/mol
97; 476 g/mol  1 nml = 2:11 10
9molec/ml:
We likewise assume the squalene synthase gene (with no further details avail-885
able) is the same concentration.886
1 - Rate of HMGCR mRNA transcription: Darzacq et al. [8] states887
12 bases are transcribed per second. Goldstein and Brown [12] say one888
HMGCoA-R gene is 24826 bases long. Therefore we have889
24826 bases
12 bases/s
= 2068:83s:
We add 30 minutes to account for post transcriptional processing steps of890
mRNA cleavage giving 3868.83s. So for one gene we have891
1 molecule
3868:83s
= 2:58 10 4 molecules/s:
A liver cell is somatic and hence diploid meaning it contains contains two892
genes, so we have893
2:58 10 4 molecules/s 2 = 5:17 10 4molecules/s:
The average cell volume is 1pl = 1  10 9ml so the rate of transcription is894
given by895
5:17 10 4 molecules/s
1 10 9ml
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giving 1 = 5:17 105 molecules/ml/s.896
2 - Rate of squalene synthase mRNA transcription: Darzacq et al. [8]897
states 12 base pairs are transcribed per second. Tansey & Shechter [37] say898
one human squalene synthase gene is over 30000 bases long. Therefore we899
have900
30000 bases
12 bases/s
= 2500s:
We add 30 minutes to account for post transcriptional processing steps of901
mRNA cleavage giving 4300 thus for one gene we have902
1 molecule
4300s
= 2:33 10 4 molecules/s:
A liver cell is somatic and hence diploid meaning it contains contains two903
genes, so we have904
2:33 10 4 molecules/s 2 = 4:65 10 4 molecules/s:
The average cell volume is 1pl = 1  10 9ml so the rate of transcription is905
given by906
4:65 10 4 molecules/s
1 10 9ml
giving 2 = 4:65 105 molecules/ml/s.907
3 - Rate of HMGCR translation: Trachsel [39] states 6 amino acids are908
translated per second. One amino acid is encoded by 3 bases or nucleotides.909
HMGCR mRNA transcript has 4475 bases (Goldstein & Brown [12]). Hence910
transcription takes:911
4475 bases
6 amino acids/s 3 amino acids/base = 248:61s;
We add 60 minutes to account for the initiation of this process912
3848:61s:
Then per ribosome we have913
1 molecule
3848:61s
= 2:60 10 4 molecules/s/ribosome:
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A ribosome can only attach every 35 bases do to its size meaning 1 mRNA914
molecule has 127:86 ribosomes attached.915
Then per mRNA molecule we have:916
2:60 10 4 molecules/s/ribosome 127:86 ribosomes/molecule
giving 3 = 3:32 10 2 /s.917
4 - Rate of squalene synthase translation: Trachsel [39] states 6 amino918
acids are translated per second. One amino acid is encoded by 3 bases919
or nucleotides. Jiang et al. [36] state that one squalene synthase mRNA920
transcript contains 2502 bases. Hence transcription takes:921
2502 bases
6 amino acids/s 3 amino acids/base = 139s;
We add 60 minutes to account for the initiation of this process922
3739s:
Then per ribosome we have923
1 molecule
3739s
= 2:67 10 4 molecules/s/ribosome:
A ribosome can only attach every 35 bases do to its size meaning 1 mRNA924
molecule has 71:49 ribosomes attached.925
Then per mRNA molecule we have:926
2:67 10 4 molecules/s/ribosome 71:49 ribosome/molecule
giving 4 = 1:91 10 2 /s.927
5 - Rate of geranyl-PP synthesis: Tanaka et al. [47] tell us that liver928
microsomes form 52 pmol mevalonate per minute per mg protein. Istvan et929
al. [15] say HMGCR is tetrameric arranged in 2 dimer, with 4 active sites,930
has molecular weight 199812 Da. The activity of the enzyme is where931
52 10 12mol/min/mg protein  52 10 12 NA:
NA = 6:022 1023 is Avagadro's constant. So we have932
52 10 12mol/min/mg protein 6:022 1023 molecules/mol
49
933
= 3:13 1013 molecules/min/mg protein:
Segel [33] says there's 1000 dierent enzymes in a cell, so for 1 mg of protein934
we have935
1 10 3g
199812g/mol 1000 = 5:00 10
 12mol:
Given there are 4 active sites per HMGA-CoA Reductase enzyme, there are936
2:0010 11moles of enzyme active sites in 1 mg of protein. Given the specic937
activity of an enzyme we nd 5 is equal to938
52 10 12 mol/min/mg
2:00 1011mol/mg = 2:60min
giving 5 = 4:33 10 2/s.939
6, 8 and 9 - Rates of farnesyl-PP, lanosterol and cholesterol syn-940
thesis: Since the value for 5 is used to describe cholesterol production from941
HMGCR, we can assume all steps in between must occur at the same rate942
or faster. Therefore we set 6, 8 and 9 equal to 4:33 10 2 /s.943
7 - Rate of squalene synthesis. Since the value for 5 is used to describe944
cholesterol production from HMGCR, we can assume all steps in between945
must occur at the same rate or faster. Therefore as an estimate we set 7946
equal to 4:33  10 2 /s. This value was then rened using local sensitivity947
analysis to give 7 = 2:17 10 1 1/s.948
K1 - Disassociation constant of SREBP-2 for HMGCR DNA: Yang949
and Swartz [29] quantifed DNA binding anities to other transcription fac-950
tors at 54:2 nmol. We convert this value into units of molecules/ml by the951
use of Avogadro's constant.952
100 10 9 moles
1000ml
 6:022 1023 molecules/mol = 3:26 1013 molecules/ml:
This value was then rened using local sensitivity analysis to give K1 =953
8:21 1012 molecules/ml.954
K2 - Disassociation constant of SREBP-2 for squalene synthase955
DNA: This was assumed equivalent to that of SREBP-2 for HMGCR DNA,956
i.e. 3.261013 molecules/ml. The value was then rened using local sensi-957
tivity analysis to give K2 = 8:21 1012 molecules/ml.958
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K3- Disassociation constant of SREBP-2 for cholesterol: Radhakr-959
ishnan et al. [46] state the binding reaction between cholesterol and SCAP960
is saturable and half-maximal binding occurs at approximately 100 nmol.961
We convert this value into units of molecules/ml by the use of Avogadro's962
constant.963
100 10 9 moles
1000 ml
 6:022 1023 molecules/mol = 6:02 1013 molecules/ml;
as an estimate we took K3 = O(10
14). This value was then rened using964
local sensitivity analysis to give K3 = 1:49 1016 molecules/ml.965
4 and  4 - Forward and reverse rates of HMGCR binding to HMG-966
CoA: These values were initially informed by assuming the ratio of 4= 4967
were the same order as those of K1, K2 and K3. We then assumed  4  4968
whereby we took an initial estimate of  4 = 1 10 3/s. These values were969
then adjusted, via a sensitivity analysis, to give the required steady-state970
cholesterol levels. This resulted in values of 4 = 1:39 10 16 ml/molecules971
s and  4 = 1:75 10 7 /s.972
5=5- Forward and reverse rates of farnesyl-PP binding to squalene973
synthase: These values were obtained in a similar manner to those of 4974
and  4. This led to 5 = 1:76 10 30 ml/molecule s and  5 = 1:75 10 5975
/s.976
K6, K7, K8, K9 and K10 -Michaelis-Menten constants of geranyl-PP,977
farnesyl-PP, lanosterol and cholesterol for HMGCR degradation978
and cholesterol for squalene synthase degradation, respectively:979
These were determined as the half-maximal values which produced a sig-980
moidal type response for each of the respective cascade products.981
1- Degradation rate of HMGCR mRNA. Degradation rates of proteins982
and mRNAs are based on their half lives, derived from an exponential decay983
model. Wilson and Deeley [3] state HMGCR mRNA has a half life of 4.3984
hours, measured in Hep G2 cells, giving 1=ln 2/15480s=4.4810 5/s.985
2 - Degradation rate of squalene synthase mRNA: This was assumed986
equivalent to that of HMGCR mRNA.987
3 - Degradation of HMGCR: Brown et al. [44] found HMGCR protein988
has a half life of 3 hours, measured in human broblast cells, such that989
3 = ln 2=10800s = 6:42 10 5/s.990
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4 - Squalene synthase degradation rate: This was assumed equivalent991
to that of HMGCR.992
5, 6 and 7 - Degradation rates of geranyl-PP, farnesyl-PP and993
lanosterol: These were assumed equivalent to that of cholesterol.994
8 - Cholesterol degradation rate: We utilise the value previously derived995
in Bhattacharya et al. [2] of 1.2010 4/s.996
! - HMGCoA production rate: This value has been determined from our997
sensitivity analysis to be 3.8951011molec./ml. The value has been found to998
ensure enough cholesterol is produced.999
xh - Number of binding sites for SREBP-2 on HMGCR DNA: Vallett1000
et al. [28] state a value of 3.1001
xs - Number of binding sites for SREBP-2 on squalene synthase1002
DNA: Without further evidence we assume this is 1.1003
xc- Number of binding sites on SREBP-2 for cholesterol: Radhakr-1004
ishnan et al. [46, 16] state a value of 4.1005
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